H L McLeod

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Pharmacogenetic analysis of clinically relevant genetic polymorphisms
    Howard L McLeod
    Department of Medicine, The Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Infect Dis 41:S449-52. 2005
  2. pmc Cancer pharmacogenetics
    S Marsh
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8069, The Siteman Cancer Center, and the CREATE Pharmacogenetic Research Network, St Louis, MO 63110 1093, USA
    Br J Cancer 90:8-11. 2004
  3. pmc RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer
    R D Church
    1Department of Surgery, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Br J Cancer 91:1015-8. 2004
  4. pmc c-erbB-2 is not a major factor in the development of colorectal cancer
    J A McKay
    Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2Z, UK
    Br J Cancer 86:568-73. 2002
  5. pmc CYP3A4 and CYP3A5 genotyping by Pyrosequencing
    Adam A Garsa
    Washington University School of Medicine, Department of Medicine, Division of Oncology, St Louis, MO 63110, USA
    BMC Med Genet 6:19. 2005
  6. ncbi request reprint Individualized cancer therapy: molecular approaches to the prediction of tumor response
    Howard L McLeod
    Washington University School of Medicine, Department of Medicine, 660 S Euclid, Campus Box 8069, St Louis, MO 63110, USA
    Expert Rev Anticancer Ther 2:113-9. 2002
  7. pmc Unfavourable expression of pharmacologic markers in mucinous colorectal cancer
    S C Glasgow
    Department of Surgery, Washington University School of Medicine, St Louis, MI, USA
    Br J Cancer 92:259-64. 2005
  8. ncbi request reprint Using genetic variation to optimize cancer chemotherapy
    Howard L McLeod
    Washington University School of Medicine, Siteman Cancer Center, St Louis, MO 63110, USA
    Clin Adv Hematol Oncol 1:107-11. 2003
  9. ncbi request reprint The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics
    Howard L McLeod
    Department of Medicine, Washington University School of Medicine, 660 S Euclid Ave Campus Box 8069, St Louis, Missouri 63110, USA
    Pharmacogenomics 3:89-98. 2002
  10. ncbi request reprint Molecular predictors of prognosis and response to therapy in colorectal cancer
    Howard L McLeod
    Washington University School of Medicine, Department of Medicine, St Louis, MO 63110 1093, USA
    Cancer Chemother Biol Response Modif 21:791-801. 2003

Collaborators

Detail Information

Publications139 found, 100 shown here

  1. ncbi request reprint Pharmacogenetic analysis of clinically relevant genetic polymorphisms
    Howard L McLeod
    Department of Medicine, The Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Infect Dis 41:S449-52. 2005
    ..Although such an approach has theoretical appeal as a means of enhancing quality and improving outcomes in this setting, several obstacles currently exist and slow the progress toward clinical application...
  2. pmc Cancer pharmacogenetics
    S Marsh
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8069, The Siteman Cancer Center, and the CREATE Pharmacogenetic Research Network, St Louis, MO 63110 1093, USA
    Br J Cancer 90:8-11. 2004
    ..In addition, the need for polygenic pharmacogenomic strategies to identify patients at risk for adverse drug reactions will be highlighted...
  3. pmc RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer
    R D Church
    1Department of Surgery, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Br J Cancer 91:1015-8. 2004
    ..We report that Cox-1 and Cox-2 expression is highly variable in Dukes' C tumours, and changes in Cox-1 expression may be of importance...
  4. pmc c-erbB-2 is not a major factor in the development of colorectal cancer
    J A McKay
    Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2Z, UK
    Br J Cancer 86:568-73. 2002
    ..05 in each case), suggesting that c-erbB-2 is not a prognostic marker in colorectal cancer...
  5. pmc CYP3A4 and CYP3A5 genotyping by Pyrosequencing
    Adam A Garsa
    Washington University School of Medicine, Department of Medicine, Division of Oncology, St Louis, MO 63110, USA
    BMC Med Genet 6:19. 2005
    ..This study describes Pyrosequencing assays for key SNPs in CYP3A4 (CYP3A4*1B, CYP3A4*2, and CYP3A4*3) and CYP3A5 (CYP3A5*3C and CYP3A5*6)...
  6. ncbi request reprint Individualized cancer therapy: molecular approaches to the prediction of tumor response
    Howard L McLeod
    Washington University School of Medicine, Department of Medicine, 660 S Euclid, Campus Box 8069, St Louis, MO 63110, USA
    Expert Rev Anticancer Ther 2:113-9. 2002
    ..This review will highlight areas of progress with use of molecular approaches to improve the prediction of tumor response, towards the goal of optimized therapy for each individual patient...
  7. pmc Unfavourable expression of pharmacologic markers in mucinous colorectal cancer
    S C Glasgow
    Department of Surgery, Washington University School of Medicine, St Louis, MI, USA
    Br J Cancer 92:259-64. 2005
    ..Likewise, DFS may be decreased in patients with mucinous tumours who receive 5-FU. The presence of mucin should be carefully evaluated in developmental trials of new agents for treating colorectal cancer...
  8. ncbi request reprint Using genetic variation to optimize cancer chemotherapy
    Howard L McLeod
    Washington University School of Medicine, Siteman Cancer Center, St Louis, MO 63110, USA
    Clin Adv Hematol Oncol 1:107-11. 2003
    ..This review will discuss recent clinically relevant examples of cancer pharmacogenetics and how genetic differences are helping to shape the future of individualized cancer chemotherapy...
  9. ncbi request reprint The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics
    Howard L McLeod
    Department of Medicine, Washington University School of Medicine, 660 S Euclid Ave Campus Box 8069, St Louis, Missouri 63110, USA
    Pharmacogenomics 3:89-98. 2002
    ..Recent studies defined target starting doses for mercaptopurine based on TPMT genotypes. This polymorphism is one of the best models for the translation of genomic information to guide patient therapeutics...
  10. ncbi request reprint Molecular predictors of prognosis and response to therapy in colorectal cancer
    Howard L McLeod
    Washington University School of Medicine, Department of Medicine, St Louis, MO 63110 1093, USA
    Cancer Chemother Biol Response Modif 21:791-801. 2003
  11. ncbi request reprint Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies
    Howard L McLeod
    Department of Medicine and The Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Clin Colorectal Cancer 4:S43-7. 2004
    ....
  12. ncbi request reprint Cancer pharmacogenomics: SNPs, chips, and the individual patient
    Howard L McLeod
    Departments of Medicine, Molecular Biology and Pharmacology, and Genetics, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Cancer Invest 21:630-40. 2003
    ....
  13. pmc Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 27:4109-15. 2009
    ..A subgroup analysis of a multisite National Cancer Institute-sponsored trial (N9741) was performed comparing outcomes of black and white patients with metastatic CRC receiving uniform treatment...
  14. pmc Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy
    N S Ferder
    Saint Louis College of Pharmacy, St Louis, MO, USA
    J Thromb Haemost 8:95-100. 2010
    ..Experts have hypothesized that genotype becomes irrelevant once international normalized ratio (INR) values are available because INR response reflects warfarin sensitivity...
  15. ncbi request reprint Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals
    H L McLeod
    Department of Medicine and Therapeutics, University of Aberdeen, UK
    Pharmacogenetics 8:195-9. 1998
    ..Erythrocyte COMT activity was lower and less thermostable in individuals with homozygous low activity alleles. The data provide molecular evidence that low COMT is less common in African individuals than the Caucasian population...
  16. ncbi request reprint Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer
    S Marsh
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Pharmacogenomics J 7:362-5. 2007
    ..Alternatively, the role of CYP1B1 in estrogen metabolism may influence the risk of invasive or paclitaxel resistant breast cancer in patients carrying the CYP1B1*3 allele...
  17. ncbi request reprint Known variant DPYD alleles do not explain DPD deficiency in cancer patients
    E S Collie-Duguid
    University of Aberdeen, Department of Medicine and Therapeutics, Institute of Medical Sciences, Foresterhill, UK
    Pharmacogenetics 10:217-23. 2000
    ..These data emphasize the complex nature of the molecular mechanisms controlling polymorphic DPD activity in vivo...
  18. ncbi request reprint Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals
    H L McLeod
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, UK
    Pharmacogenetics 9:773-6. 1999
    ..This study confirms ethnic differences in the predominant mutant TPMT allele and the findings will be useful for the development of polymerase chain reaction-based strategies to prevent toxicity with thiopurine medications...
  19. ncbi request reprint Cancer pharmacogenomics: current and future applications
    James W Watters
    Department of Medicine, Washington University School of Medicine, 660 S Euclid Ave Campus Box 8069, St Louis, MO 63110, USA
    Biochim Biophys Acta 1603:99-111. 2003
    ..The power and utility of the mouse as an experimental system for pharmacogenomic discovery will also be discussed in the context of cancer therapy...
  20. ncbi request reprint MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity
    M M Ameyaw
    University of Aberdeen, Department of Medicine and Therapeutics, Institute of Medical Sciences, Foresterhill, Aberdeen, UK
    Pharmacogenetics 11:217-21. 2001
    ..The high frequency of the C allele in the African group implies overexpression of PGP and may have important therapeutic and prognostic implications for use of PGP dependent drugs in individuals of African origin...
  21. ncbi request reprint Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy
    S C Pritchard
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen AB25 2ZD, UK
    Oncol Rep 8:421-4. 2001
    ..These results suggest that a broad spectrum MMP inhibitor is worthy of evaluation as a therapeutic method of reducing tumor invasion and metastasis in stage II NSCLC...
  22. ncbi request reprint Expression of drug pathway proteins is independent of tumour type
    W Zhang
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA, and Department of Pathology, Free University Hospital, Amsterdam, The Netherlands
    J Pathol 209:213-9. 2006
    ..Cluster analysis identified a variety of tumours with the same pharmacological profile. The anatomy independence of drug pathways stimulates efforts to move away from our traditional approaches to the selection of cancer therapy...
  23. ncbi request reprint Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer
    S Marsh
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK
    Int J Oncol 19:383-6. 2001
    ..This is consistent with previous studies where higher TS expression was associated with poor response to TS inhibitors. Prospective analysis of the influence of the TS polymorphism on patient outcome is warranted...
  24. ncbi request reprint Novel thymidylate synthase enhancer region alleles in African populations
    S Marsh
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom
    Hum Mutat 16:528. 2000
    ..This is a unique example suggesting the influence of multiple selection pressures within individual populations. Hum Mutat 16:528, 2000...
  25. ncbi request reprint Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases
    J A McKay
    Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, AB25 2ZD, Aberdeen, UK
    Eur J Cancer 38:2258-64. 2002
    ..05). These results indicate that while EGFR overexpression is a common event in colorectal carcinogenesis, it does not influence patient prognosis...
  26. pmc Colorectal cancer genomics: evidence for multiple genotypes which influence survival
    P H Rooney
    Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, AB25 2ZD, Aberdeen
    Br J Cancer 85:1492-8. 2001
    ..Although genomic change in CRC is relevant to the survival of patients with Dukes' C CRC, careful analysis is required to identify cell lines which are representative models of CRC genomics...
  27. ncbi request reprint Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034
    H L McLeod
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, United Kingdom
    Clin Cancer Res 6:2677-84. 2000
    ..This study demonstrates rapid systemic clearance of AG2034 and suggests pharmacokinetic approaches that may minimize patient toxicity and aid the development of this interesting class of anticancer agents...
  28. ncbi request reprint Cloning and initial characterization of the human DPYD gene promoter
    E S Collie-Duguid
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, AB25 2ZD, United Kingdom
    Biochem Biophys Res Commun 271:28-35. 2000
    ..Further insight into regulation of DPD expression may identify new avenues for the treatment of clinical problems associated with DPD deficiency...
  29. pmc A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans
    D Voora
    Department of Medicine, Washington University in St Louis, St Louis, Missouri, USA
    Clin Pharmacol Ther 87:445-51. 2010
    ..14, one-sided P = 0.03). CALU rs339097 A>G is associated with higher warfarin dose requirements, independent of known genetic and nongenetic predictors of warfarin dose in African Americans...
  30. ncbi request reprint A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report
    Giancarlo A Pillot
    Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Thorac Oncol 1:972-8. 2006
    ..In addition, we studied the correlation between certain genotypes of enzymes involved in irinotecan metabolism with efficacy and toxicity...
  31. pmc A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes
    Lang Li
    Division of Biostatistics, Department of Medicine, Indiana University, Indianapolis, Indiana46202, USA
    J Biopharm Stat 18:1150-77. 2008
    ..The mixture model approach has the highest recovery probability to recover the true partition in the simulation studies. Its applications are exemplified in interim data analyses for two cancer studies...
  32. ncbi request reprint Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases
    J A McKay
    Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, Scotland, United Kingdom
    Clin Cancer Res 6:1113-8. 2000
    ..In addition, PCNA-labeling indices between paired samples were neither consistently higher nor lower, suggesting that the proliferative capacity of tumor cells is not directly related to their ability to metastasize...
  33. ncbi request reprint Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors
    W Wang
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom
    Cancer Res 61:5505-10. 2001
    ..These data provide encouragement that comprehensive transcript analysis will aid the quest for more enlightened therapeutics...
  34. ncbi request reprint The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
    E S Collie-Duguid
    The University of Aberdeen, Department of Medicine and Therapeutics, Institute of Medical Sciences, Foresterhill, UK
    Pharmacogenetics 9:37-42. 1999
    ..TPMT*2 appears to be a more recent allele, which has only been detected in Caucasians to date. These ethnic differences may be important in the clinical use of thiopurine drugs...
  35. doi request reprint Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies
    B R Tan
    Division of Medical Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Ann Oncol 19:1742-8. 2008
    ..Oxaliplatin, gemcitabine and capecitabine are all active agents against upper gastrointestinal and pancreaticobiliary cancers...
  36. ncbi request reprint Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance
    M C McFadyen
    Department of Pathology, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
    Biochem Pharmacol 62:207-12. 2001
    ..This study is the first to indicate that the presence of CYP1B1 in cells decreases their sensitivity to the cytotoxic effects of a specific anticancer drug...
  37. ncbi request reprint Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?
    B Rochat
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, UK
    J Pharmacol Exp Ther 296:537-41. 2001
    ..The results obtained indicate that several anticancer agents inhibit CYP1B1 activity. Drug inactivation by CYP1B1 may represent a novel mechanism of resistance, influencing the clinical outcome of chemotherapy...
  38. ncbi request reprint Analysis of uracil DNA glycosylase in human colorectal cancer
    C Dusseau
    Department of Medicine and Therapeutics, Aberdeen Royal Infirmary, University of Aberdeen, UK
    Int J Oncol 18:393-9. 2001
    ..The high tumor:normal tissue ratio supports further interest in base excision repair, through UDG, as a potential source of fluoropyrimidine resistance in colorectal cancer...
  39. pmc Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
    S A Ridge
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, UK
    Br J Cancer 77:497-500. 1998
    ..These studies highlight the need to combine DPD genotype and phenotype analysis to identify mutations that result in reduced enzyme activity...
  40. ncbi request reprint Thymidylate synthase pharmacogenetics in colorectal cancer
    S Marsh
    Washington University School of Medicine, Departments of Medicine, Molecular Biology and Pharmacology, and Genetics, Siteman Cancer Center, St. Louis, MO, USA
    Clin Colorectal Cancer 1:175-8; discussion 179-81. 2001
    ..Prospective confirmation of the impact of TSER on outcome, after TS-targeted chemotherapy, will define the utility of pharmacogenetics to optimize the selection of 5-FU therapy for colorectal cancer...
  41. doi request reprint Irinotecan pharmacogenetics: influence of pharmacodynamic genes
    Janelle M Hoskins
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Cancer Res 14:1788-96. 2008
    ..We undertook a retrospective candidate gene haplotype association study to investigate this hypothesis...
  42. ncbi request reprint Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer
    R G Jaffrey
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Scotland
    Cancer Res 60:4349-52. 2000
    ..Additional investigations may shed light on the mechanistic impact of the mitotic spindle checkpoint pathway in colorectal tumor initiation and progression...
  43. ncbi request reprint Pharmacogenomic assessment of carboxylesterases 1 and 2
    Sharon Marsh
    Department of Medicine, Washington University School of Medicine and the Siteman Cancer Center, St Louis, MO 63110, USA
    Genomics 84:661-8. 2004
    ..Functional analysis of the novel polymorphisms described in this study is now warranted to identify putative roles in drug metabolism...
  44. pmc Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?
    P Ranganathan
    Division of Rheumatology and Department of Medicine, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110, USA
    Ann Rheum Dis 62:4-9. 2003
    ..However, a significant number of patients with RA either do not benefit from the drug or are unable to tolerate it. Pharmacogenetic approaches may help optimise treatment with MTX, and also other agents, in RA...
  45. ncbi request reprint Therapeutic opportunities from tumour biology in metastatic colon cancer
    H L McLeod
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD, Aberdeen, UK
    Eur J Cancer 36:1706-12. 2000
    ....
  46. ncbi request reprint Interethnic variability of ERCC2 polymorphisms
    C R King
    Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO 63110, USA
    Pharmacogenomics J 5:54-9. 2005
    ..This information on ERCC2 genomic structure will allow the construction of definitive studies to clarify the clinical role of this important gene...
  47. pmc Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours
    H L McLeod
    Department of Medicine, University of Aberdeen, Foresterhill, UK
    Br J Cancer 77:461-5. 1998
    ..As a large degree of the variation in tumour DPD activity is not explained by PMNC activity, more accurate alternatives are needed before DPD activity can be used for targeting 5-FU therapy...
  48. ncbi request reprint Ethnic differences in pharmacogenetically relevant genes
    R M Engen
    Department of Medicine, Washington University School of Medicine and the Siteman Cancer Center, St Louis, Missouri 63110, USA
    Curr Drug Targets 7:1641-8. 2006
    ..Understanding the influence of ethnicity on pharmacogenomics will allow for comprehensive strategies for using the genome to optimize therapy for patients throughout the world...
  49. ncbi request reprint Pharmacogenetic analysis of clinically relevant genetic polymorphisms
    Christine M Rose
    Washington University School of Medicine, St Louis, MO, USA
    Methods Mol Med 85:225-37. 2003
  50. ncbi request reprint Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
    Deepak Voora
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Thromb Haemost 93:700-5. 2005
    ..Prospective, perioperative pharmacogenetics-based dosing of warfarin is feasible; however, further evaluation in a randomized, controlled study is recommended...
  51. ncbi request reprint Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans
    David E Lanfear
    Washington University School of Medicine, Department of Medicine, St Louis, Missouri 63110 1093, USA
    J Am Coll Cardiol 44:165-7. 2004
    ..This study was designed to describe the frequencies of multiple myocardial infarction (MI) risk-associated genotypes among different racial groups...
  52. ncbi request reprint Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis
    Prabha Ranganathan
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA prangana im wustl edu
    Pharmacogenomics 5:559-69. 2004
    ..Whether such differences contribute to a differential response to MTX in patients with RA deserves to be investigated...
  53. ncbi request reprint Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian population
    M M Ameyaw
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK
    Hum Mutat 16:445-6. 2000
    ....
  54. pmc Amplification of fluorescent in situ hybridisation signals in formalin fixed paraffin wax embedded sections of colon tumour using biotinylated tyramide
    J A McKay
    Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, UK
    Mol Pathol 50:322-5. 1997
    ....
  55. ncbi request reprint Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer
    E S Collie-Duguid
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland
    Int J Cancer 94:297-301. 2001
    ..This suggests the presence of co-ordinated regulation of these pyrimidine metabolic enzymes and offers a strategy for optimising the use of pyrimidine-based chemotherapy...
  56. pmc CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia
    M T Tayeb
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresthill, UK
    Br J Cancer 88:928-32. 2003
    ..43; 95% CI=0.99-11.77). While independent confirmation is required in further studies, these results provide a potential tool to assist prediction strategies for this important disease...
  57. ncbi request reprint Pharmacogenomics: unlocking the human genome for better drug therapy
    H L McLeod
    Department of Medicine, Division of Oncology, Washington University Medical School, St Louis, Missouri 63110 1093, USA
    Annu Rev Pharmacol Toxicol 41:101-21. 2001
    ..This review highlights the current status of work in this field and addresses strategies that hold promise for future advances in pharmacogenomics...
  58. pmc Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer
    M C McFadyen
    Departments of Pathology, Obstetrics and Gynaecology, Medicine and Therapeutics, Molecular and Cell Biology, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
    Br J Cancer 85:242-6. 2001
    ..005 Spearman's rank correlation test). In contrast no detectable CYP1B1 was found in normal ovary...
  59. ncbi request reprint Cyclo-oxygenase 2 inhibition in colorectal cancer therapy
    R D Church
    Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110 1093, USA
    Br J Surg 90:1055-67. 2003
    ..These drugs have implications for both the prevention of colorectal carcinoma and the potential treatment of the disease...
  60. ncbi request reprint Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia
    H L McLeod
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen
    Br J Haematol 105:696-700. 1999
    ..This study demonstrates that 11.6% of the children had variant TPMT alleles. Prospective identification of TPMT genotype may be a promising tool for decreasing excessive haematological toxicity in individuals with low activity...
  61. ncbi request reprint Nomenclature for human DPYD alleles
    H L McLeod
    Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, UK
    Pharmacogenetics 8:455-9. 1998
    ..The number specifies the key mutation and, where appropriate, a letter following the number indicates an additional mutation on the mutant allele. Criteria for classification as a distinct allele are also presented...
  62. ncbi request reprint Pyrosequencing of clinically relevant polymorphisms
    Sharon Marsh
    Division of Molecular Oncology, Washington University School of Medicine, St Louis, MO, USA
    Methods Mol Biol 311:97-114. 2005
    ..Assays details for Pyrosequencing of clinically relevant polymorphisms are described in this chapter...
  63. ncbi request reprint Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups
    Taylor J Maxwell
    Department of Biology, Washington University in St Louis, St Louis, MO 63110 1093, USA
    Int J Mol Med 16:573-80. 2005
    ..Further studies are needed to see if functional relationships are the same across populations...
  64. ncbi request reprint Polymorphism discovery in 51 chemotherapy pathway genes
    Robert R Freimuth
    Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
    Hum Mol Genet 14:3595-603. 2005
    ..These results provide experimental validation and estimated allele frequencies for polymorphisms in three common ethnic groups and facilitate applied pharmacogenetic studies of anticancer drugs...
  65. ncbi request reprint Pharmacogenetic influences on treatment response and toxicity in colorectal cancer
    Benjamin R Tan
    Department of Medicine and The Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
    Semin Oncol 32:113-9. 2005
    ..Validation of these predictive factors in prospective clinical trials is now necessary to allow for a rational and systematic individualization of cancer therapy...
  66. ncbi request reprint Pharmacogenomics of cancer chemotherapy-induced toxicity
    C Ryan Miller
    Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA
    J Support Oncol 5:9-14. 2007
    ..This review will discuss clinically relevant examples of gene polymorphisms that influence toxicity and the experimental tools that have been utilized for discovering toxicity-related polymorphisms...
  67. pmc Application of laser capture microdissection and proteomics in colon cancer
    L C Lawrie
    Department of Pathology, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
    Mol Pathol 54:253-8. 2001
    ..CONCLUSION: A method for performing two dimensional gel electrophoresis and mass spectrometry using laser capture microdissected tissue has been developed...
  68. ncbi request reprint Evaluation of the linearity of docetaxel pharmacokinetics
    H L McLeod
    Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, UK
    Cancer Chemother Pharmacol 42:155-9. 1998
    ..The presence of nonlinear docetaxel pharmacokinetics at doses above 115 mg/m2 will have to be determined in case of further dose escalation...
  69. ncbi request reprint Thiopurine methyltransferase alleles in British and Ghanaian populations
    M M Ameyaw
    University of Aberdeen, Department of Medicine and Therapeutics, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK
    Hum Mol Genet 8:367-70. 1999
    ..This study provides the first analysis of TPMT mutant allele frequency in an African population and indicates that, unlike Caucasians, TPMT*3C is the most common allele in African subjects...
  70. pmc Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034
    D Bissett
    Department of Medicine and Therapeutics, University of Aberdeen, UK
    Br J Cancer 84:308-12. 2001
    ..The AG2034 AUC(0-24)increased by a median of 184% (range 20-389%) from cycle 1 to 3 in all 10 patients examined. No objective antitumour responses were observed in the study...
  71. pmc Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    B F Gage
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Pharmacol Ther 84:326-31. 2008
    ..To facilitate use of these pharmacogenetic and clinical algorithms, we developed a nonprofit website, http://www.WarfarinDosing.org...
  72. pmc Mutations at codon 974 of the DPYD gene are a rare event
    S A Ridge
    Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, UK
    Br J Cancer 75:178-9. 1997
    ..We detected no mutations in the 606 alleles studied and conclude that mutations at codon 974 are a rare event...
  73. ncbi request reprint Pharmacogenetics and pediatric cancer
    Lisa Bomgaars
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer J 11:314-23. 2005
    ....
  74. ncbi request reprint Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome
    David E Lanfear
    Departments of Medicine, Genetics, and Molecular Biology and Pharmacology, Washington University School of Medicine, St Louis, MO
    JAMA 294:1526-33. 2005
    ..However, no associations between these polymorphisms and mortality have been demonstrated...
  75. ncbi request reprint Concordance of pharmacogenetic markers in germline and colorectal tumor DNA
    Sharon Marsh
    Washington University School of Medicine, Campus Box 8069 660 South Euclid AvenueSt Louis, MO 63110, USA
    Pharmacogenomics 6:873-7. 2005
    ..However, this relies on the assumption that germline DNA is representative of the tumor genotype. To date, there has been little attention paid to defining the relationship between tumor and germline genomes...
  76. ncbi request reprint Systems pharmacogenomics in yeast
    Patrick Cahan
    Washington University School of Medicine, Department of Medicine, Division of Oncology, Computational Biology Program, St Louis, Missouri 63110, USA
    Pharmacogenomics 7:255-9. 2006
    ..The screens identified genes in well-characterized DNA, in addition to genes whose role in DNA-damage-response pathways had not previously been established...
  77. ncbi request reprint Pharmacokinetics after endovascular lung perfusion with Cisplatin
    Daniel B Brown
    Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Box 8131, St Louis, Missouri 63110, USA
    J Vasc Interv Radiol 17:883-8. 2006
    ..Endovascular lung perfusion (ELP) is a technique designed to deliver high doses of cisplatin via the pulmonary artery for the treatment of lung tumors. The purpose of the current study was to evaluate variables that affect adduct formation...
  78. ncbi request reprint Pharmacogenetics and oncology treatment for breast cancer
    Sharon Marsh
    Washington University School of Medicine, Division of Oncology, St Louis, MO 63110, USA
    Expert Opin Pharmacother 8:119-27. 2007
    ..DNA variations in metabolism, transport and drug target genes may contribute to chemotherapy efficacy and toxicities. The status of the identification of genetic markers for breast cancer therapy selection is highlighted in this review...
  79. ncbi request reprint Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer
    Sharon Marsh
    Washington University School of Medicine, Division of Oncology, St Louis, MO 63110, USA
    J Clin Oncol 25:4528-35. 2007
    ....
  80. ncbi request reprint Identification of NR1I2 genetic variation using resequencing
    Cristi R King
    Department of Medicine, Washington University School of Medicine, St Louis, MO, 63110, USA
    Eur J Clin Pharmacol 63:547-54. 2007
    ..This heterodimer binds to the nuclear receptor response elements of downstream genes such as ABCB1, CYP2C, and CYP3A. This study determined the extent of NR1I2 variation in three world populations...
  81. ncbi request reprint Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model
    Daniel B Brown
    Mallinckrodt Institute of Radiology, Alvin J Siteman Cancer Center, St Louis, MO 63110, USA
    Oncol Rep 11:237-43. 2004
    ..Further study of ELP evaluating the acute and chronic effects of repeated treatment administration is warranted...
  82. doi request reprint CANDID: a flexible method for prioritizing candidate genes for complex human traits
    Janna E Hutz
    Division of Statistical Genomics, Washington University School of Medicine, Saint Louis, Missouri, USA
    Genet Epidemiol 32:779-90. 2008
    ..Its accuracy and ease of use make CANDID a highly useful tool in study design and analysis for complex human traits...
  83. pmc Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes
    Sharon Cresci
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8086, Saint Louis, MO 63110 1093, USA
    Pharmacogenomics 9:1403-17. 2008
    ....
  84. pmc A high-resolution map of segmental DNA copy number variation in the mouse genome
    Timothy A Graubert
    Department of Medicine, Division of Oncology, Stem Cell Biology Section, Washington University, St Louis, Missouri, United States of America
    PLoS Genet 3:e3. 2007
    ..Annotation of CNVs in the mouse genome combined with sequence-based analysis provides an important resource that will help define the genetic basis of complex traits...
  85. pmc Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers
    Jinsheng Yu
    Washington University School of Medicine, Department of Pathology and Immunology, Saint Louis, MO, USA
    Pharmacogenomics 9:1459-66. 2008
    ....
  86. ncbi request reprint DNA repair pathway profiling and microsatellite instability in colorectal cancer
    Jinsheng Yu
    Department of Medicine, Washington University School of Medicine and Siteman Cancer Center, Saint Louis, Missouri 63110 1093, USA
    Clin Cancer Res 12:5104-11. 2006
    ..DNA repair is conducted by distinct pathways of genes, many of which are thought to be altered in colorectal cancer. However, there has been little characterization of these pathways in colorectal cancer...
  87. ncbi request reprint Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis
    Prabha Ranganathan
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Rheumatol 35:572-9. 2008
    ..We examined the influence of MTX transporter gene polymorphisms on MTX toxicity in 2 racial groups of patients with RA...
  88. ncbi request reprint Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
    Brian F Gage
    Department of Medicine, Washington University School of Medicine Campus Box 8005, 660 S Euclid Ave St Louis, Missouri 63110, USA
    Thromb Haemost 91:87-94. 2004
    ..001). In conclusion, the maintenance warfarin dose can be estimated from demographic, clinical, and pharmacogenetic factors that can be obtained at the time of warfarin initiation...
  89. ncbi request reprint Pharmacogenetics of irinotecan toxicity
    Sharon Marsh
    Washington University, School of Medicine, Division of Oncology, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110, USA
    Pharmacogenomics 5:835-43. 2004
    ..Prospective screening of patients prior to chemotherapy selection may reduce the frequency of severe toxicities by allowing alternate therapy selections for patients carrying the UGT1A1*28 polymorphism...
  90. ncbi request reprint Pharmacogenomics: the influence of genomic variation on drug response
    Fabienne J Thomas
    Washington University School of Medicine, Department of Medicine, Campus Box 8069, St Louis, MO 63110, USA
    Curr Top Med Chem 4:1399-409. 2004
    ..This review will discuss clinically relevant examples of genetic polymorphisms that influence the outcome of drug therapy, and possibilities for future applications of pharmacogenomics...
  91. ncbi request reprint Distribution of ITPA P32T alleles in multiple world populations
    Sharon Marsh
    Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110, USA
    J Hum Genet 49:579-81. 2004
    ..This data provides a foundation on which prospective screening studies can be planned to identify patients at risk for severe toxicity from azathioprine therapy...
  92. ncbi request reprint Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer
    Elizabeth A Kidd
    Department of Medicine, Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Clin Cancer Res 11:2612-9. 2005
    ..These variations in gene expression could provide valuable insights for optimizing treatment selection for patients with colorectal cancer...
  93. ncbi request reprint Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase
    Ranjeet Ahluwalia
    Washington University School of Medicine, Division of Oncology, St Louis, MO 63110, USA
    Clin Chem 49:1661-4. 2003
  94. ncbi request reprint Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report
    Ramaswamy Govindan
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Oncology (Williston Park) 17:27-31. 2003
    ..However, this combination chemotherapy regimen has an unacceptable rate of febrile neutropenia. This regimen needs to be modified to reduce the incidence of febrile neutropenia...
  95. ncbi request reprint Analysis of variation in mouse TPMT genotype, expression and activity
    James W Watters
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Pharmacogenetics 14:247-54. 2004
    ..In addition, the identified pattern of low haplotype diversity suggests that the mouse is likely to be useful for pharmacogenomic discovery by associating haplotype blocks with drug response phenotypes among inbred strains...
  96. ncbi request reprint Challenges of implementing pharmacogenetics in the critical care environment
    Bradley D Freeman
    Department of Surgery, Washington University School of Medicine, 660 S Euclid Avenue, Box 8109, St Louis, Missouri 63110, USA
    Nat Rev Drug Discov 3:88-93. 2004
  97. pmc Genome-wide discovery of loci influencing chemotherapy cytotoxicity
    James W Watters
    Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110, USA
    Proc Natl Acad Sci U S A 101:11809-14. 2004
    ....
  98. ncbi request reprint Use of pharmacogenetics to guide warfarin therapy
    Deepak Voora
    Departments of Medicine and Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Drugs Today (Barc) 40:247-57. 2004
    ..The genotype assays for genetic variants relevant to warfarin are widely used and are being developed for commercial use (5), making the promise of a pharmacogenetics-based approach a near reality...
  99. ncbi request reprint Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure
    David E Lanfear
    Washington University School of Medicine, Department of Medicine, 660 S Euclid Ave, Campus Box 8069, St Louis, MO 63110 1093, USA
    Pharmacogenomics 5:553-8. 2004
    ..This study provides the first look into the population frequency of these compound genotypes, and it provides the necessary first step for future evaluation of polygenic strategies to individualize therapy for heart failure...
  100. ncbi request reprint Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis
    Prabha Ranganathan
    Division of Rheumatology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Arthritis Rheum 54:1366-77. 2006
  101. ncbi request reprint A mouse-based strategy for cyclophosphamide pharmacogenomic discovery
    James W Watters
    Washington Univ School of Medicine, Dept of Medicine, Campus Box 8069, St Louis, MO 63110, USA
    J Appl Physiol 95:1352-60. 2003
    ..This phenotypic and genotypic variation among inbred strains provides a framework for cyclophosphamide pharmacogenomic discovery...